Last reviewed · How we verify
Triamcinolone Acetonide 0.1% Oint
Triamcinolone acetonide is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the cytoplasm.
Triamcinolone acetonide is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Allergic contact dermatitis, Lichen planus.
At a glance
| Generic name | Triamcinolone Acetonide 0.1% Oint |
|---|---|
| Also known as | Group I |
| Sponsor | Al-Azhar University |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
The drug translocates to the nucleus and modulates gene transcription, reducing production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of local inflammatory responses at the site of application. As a topical ointment formulation, it provides localized anti-inflammatory and immunosuppressive effects on the skin.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
- Allergic contact dermatitis
- Lichen planus
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
- Systemic absorption (with prolonged use or occlusion)
Key clinical trials
- Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (PHASE4)
- Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment (PHASE2, PHASE3)
- The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (PHASE4)
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2, PHASE3)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Mechlorethamine Induced Contact Dermatitis Avoidance Study (PHASE2)
- Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone Acetonide 0.1% Oint CI brief — competitive landscape report
- Triamcinolone Acetonide 0.1% Oint updates RSS · CI watch RSS
- Al-Azhar University portfolio CI